Point-Of-Care Lateral Flow Reader Delivers High-Sensitivity Measurements In 10 Seconds
|
By LabMedica International staff writers Posted on 12 Aug 2024 |

A customizable point-of-care (POC) lateral flow reader combines advanced imaging technology and proprietary algorithms to deliver high-sensitivity measurements in just 10 seconds.
The miniDxR lateral flow reader designed by DCN Dx (Carlsbad, CA, USA) for POC testing offers advanced imaging technology, superior sensitivity and specificity, and robust cybersecurity features. It is customizable for diverse diagnostic applications, providing reliable and accurate results in diverse POC settings. The miniDxR utilizes advanced camera-based colorimetry and fluorescence for accurate and precise color and intensity detection, vital for the most sensitive POC diagnostics. It features a modular cartridge nest that can be customized to accommodate a wide variety of lateral flow assay cassettes, ensuring compatibility with a laboratory’s specific needs.
The miniDxR boasts a user-friendly interface with a vibrant color display and simple three-button control, enabling effortless operation even in fast-paced POC environments and while using gloves. Additional options are available to adapt screen size and button controls. It offers versatile “batch” and “single test” modes to accommodate diverse testing protocols, allowing labs to analyze pre-run assays or monitor lateral flow assays in real-time at the POC. Additionally, the miniDxR safeguards sensitive data with robust encryption and adheres to rigorous international standards, including FCC, IEC 61326, IEC 61010, IEC 60601, and IEC 62304, ensuring suitability for POC use.
The miniDxR offers a variety of customization options, from software workflows and data presentation to hardware modifications and branding. Every customized miniDxR unit comes with standard features such as pre-submission materials, product and software requirements, risk analysis, cybersecurity measures, verifications, and completion of the Design History File per FDA requirements. The miniDxR is designed to excel in both sophisticated clinical labs and challenging field environments.
"From its advanced capabilities to its range of customization options, our team designed this reader with the specific needs of point-of-care testing in mind," said Pat Vaughan, Ph.D., COO of DCN Dx.
Related Links:
DCN Dx
Latest Molecular Diagnostics News
- Fapon Showcases AI-Engineered Enzymes and RNA Workflows at AMP 2026
- AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
- Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
- Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
- Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment
- Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
- AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
- AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
- Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations
- Blood Test Identifies Candidates for Targeted Radiotherapy in Advanced Prostate Cancer
- Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma
- Liquid Biopsy Captures Gene Activity Patterns in Small-Cell Lung Cancer
- Genomic Sequencing Identifies Actionable Findings to Guide Rare Disease Management
- Combined Blood Tests Help Clarify Colorectal Cancer Recurrence Risk
- Blood RNA Test May Detect Precursors to Ovarian Cancer
- Microsatellite Instability Test Gains FDA Approval for Immunotherapy Selection
Channels
Clinical Chemistry
view channel
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
New WHO Tools Address Gaps in Antimicrobial Resistance Testing
Antimicrobial resistance (AMR) is a growing global health threat, making infections increasingly difficult to diagnose and treat as they become resistant to standard antibiotics. Its spread is driven partly... Read more
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians
Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







